Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group. European journal of cancer (Oxford, England : 1990) [Eur J Cancer] Journal article | | Title | Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group. | | Author(s) | Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M, for the German Adjuvant Breast Cancer Group | | Institution | Frauenklinik vom Roten Kreuz, Taxistrasse 3, 80637 München, Germany. | | Source | Eur J Cancer 2009 Oct 29. | | Abstract | To compare dose-intensified epirubicin monotherapy with a standard sequential regimen, patients with primary breast cancer and 10 involved axillary nodes were randomised to either four 21-day cycles of epirubicin 120mg/m(2) (E120; n=202) or four 21-day cycles of epirubicin 90mg/m(2) plus cyclophosphamide 600mg/m(2) (EC) followed by three 28-day cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF; n=209). Simultaneous hormonal treatment was applied in both arms. At 5years' median follow-up, the 5-year event-free survival (EFS) rates were 47.7% (95% confidence interval [CI], 40.2-55.2%) for E120 and 45.9% (38.5-53.3%) for EC-CMF. E120 was as effective as EC-CMF with regard to EFS (hazard ratio [HR] for E120 versus EC-CMF 1.04; 95% CI, 0.79-1.36; p=0.79) and overall survival (HR 1.06; 95% CI 0.77-1.46; p=0.72). The data demonstrate that 4 cycles of dose-intensified epirubicin monotherapy can be as effective as 7 cycles of standard sequential polychemotherapy in high-risk breast cancer patients with 10 positive lymph nodes, despite treatment with a single agent and a shorter treatment duration. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19879750 |
|
|
| |
Advertise on this site.
| | |
|
